See more : K K Fincorp Limited (KKFIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Smith & Nephew plc (SNN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Smith & Nephew plc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Link Prop Investment AB (publ) (LINKAB.ST) Income Statement Analysis – Financial Results
- GLAD CUBE Inc. (9561.T) Income Statement Analysis – Financial Results
- Xerox Holdings Corporation (XRX) Income Statement Analysis – Financial Results
- Lan Fa Textile Co.,Ltd. (1459.TW) Income Statement Analysis – Financial Results
- Zhejiang Jiaxin Silk Corp., Ltd. (002404.SZ) Income Statement Analysis – Financial Results
Smith & Nephew plc (SNN)
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.55B | 5.22B | 5.21B | 4.56B | 5.14B | 4.90B | 4.77B | 4.67B | 4.63B | 4.62B | 4.35B | 4.14B | 4.27B | 3.96B | 3.77B | 3.80B | 3.37B | 2.78B | 2.55B | 2.39B | 2.11B | 1.79B | 1.58B | 1.69B | 1.81B | 1.75B | 1.73B | 1.83B | 1.59B | 1.51B | 1.40B | 1.30B | 1.48B | 1.41B | 1.14B | 1.08B | 1.02B | 709.77M | 609.40M |
| Cost of Revenue | 1.73B | 1.52B | 1.51B | 1.38B | 1.33B | 1.30B | 1.25B | 1.27B | 1.14B | 1.13B | 1.08B | 1.07B | 1.14B | 1.03B | 1.03B | 1.08B | 994.00M | 769.00M | 701.00M | 642.17M | 616.25M | 531.63M | 509.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.82B | 3.70B | 3.70B | 3.18B | 3.81B | 3.61B | 3.52B | 3.40B | 3.49B | 3.49B | 3.27B | 3.07B | 3.13B | 2.93B | 2.74B | 2.72B | 2.38B | 2.01B | 1.85B | 1.75B | 1.49B | 1.26B | 1.07B | 1.69B | 1.81B | 1.75B | 1.73B | 1.83B | 1.59B | 1.51B | 1.40B | 1.30B | 1.48B | 1.41B | 1.14B | 1.08B | 1.02B | 709.77M | 609.40M |
| Gross Profit Ratio | 68.82% | 70.85% | 70.95% | 69.71% | 74.09% | 73.53% | 73.81% | 72.76% | 75.33% | 75.59% | 75.11% | 74.14% | 73.30% | 73.98% | 72.69% | 71.67% | 70.50% | 72.33% | 72.53% | 73.18% | 70.73% | 70.26% | 67.63% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 299.00M | 442.00M | 397.00M | 307.00M | 292.00M | 246.00M | 223.00M | 230.00M | 222.00M | 235.00M | 231.00M | 171.00M | 167.00M | 151.00M | 155.00M | 152.00M | 142.00M | 120.00M | 122.00M | 127.36M | 119.29M | 98.79M | 74.12M | 69.30M | 73.12M | 71.54M | 69.27M | 70.73M | 45.43M | 45.34M | 43.04M | 36.86M | 37.80M | 32.79M | 22.79M | 23.79M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 384.00M | 2.88B | 2.72B | 2.56B | 2.69B | 2.50B | 2.36B | 2.37B | 2.64B | 0.00 | 2.06B | 2.05B | 2.10B | 1.86B | 1.86B | 1.94B | 1.74B | 1.32B | 689.00M | 1.15B | 975.54M | 872.14M | 750.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.22B | 2.07B | 2.01B | 1.77B | 1.91B | 1.82B | 1.78B | 1.71B | 1.74B | 0.00 | 91.00M | 1.44B | 0.00 | 0.00 | 0.00 | 1.80B | 1.53B | 1.32B | 1.21B | 0.00 | 853.57M | -307.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.60B | 2.70B | 2.64B | 2.44B | 2.53B | 2.38B | 2.42B | 2.26B | 2.52B | 2.32B | 2.15B | 2.05B | 2.10B | 1.86B | 1.86B | 1.80B | 1.53B | 1.32B | 1.21B | 1.15B | 975.54M | 872.14M | 750.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 493.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00M | 0.00 | 0.00 | -4.00M | 0.00 | -87.50M | -58.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.39B | 3.39B | 3.04B | 2.88B | 3.01B | 2.77B | 2.59B | 2.29B | 2.89B | 2.75B | 2.47B | 2.22B | 2.27B | 2.01B | 2.02B | 2.08B | 1.77B | 1.45B | 1.35B | 1.28B | 1.09B | 1.52B | 839.35M | 1.60B | 1.65B | 1.51B | 1.45B | 1.52B | 1.33B | 1.02B | 1.18B | 1.10B | 1.12B | 1.41B | 1.14B | 1.08B | 1.02B | 709.77M | 609.40M |
| Cost & Expenses | 5.12B | 4.91B | 4.55B | 4.26B | 4.34B | 4.07B | 3.84B | 3.56B | 4.04B | 3.88B | 3.55B | 3.29B | 3.41B | 3.04B | 3.05B | 3.16B | 2.76B | 2.22B | 2.05B | 1.92B | 1.71B | 1.52B | 1.35B | 1.60B | 1.65B | 1.51B | 1.45B | 1.52B | 1.33B | 1.02B | 1.18B | 1.10B | 1.12B | 1.41B | 1.14B | 1.08B | 1.02B | 709.77M | 609.40M |
| Interest Income | 34.00M | 66.00M | 74.00M | 56.00M | 55.00M | 51.00M | 51.00M | 46.00M | 38.00M | 22.00M | 4.00M | 11.00M | 4.00M | 3.00M | 2.00M | 5.00M | 10.00M | 19.00M | 27.00M | 32.22M | 19.64M | 0.00 | 0.00 | 6.57M | 16.66M | 13.45M | 14.22M | 7.36M | 10.35M | 17.98M | 26.33M | 37.01M | 49.59M | 53.62M | 30.81M | 21.98M | 27.17M | 18.04M | 17.14M |
| Interest Expense | 139.00M | 80.00M | 80.00M | 62.00M | 65.00M | 59.00M | 57.00M | 52.00M | 50.00M | 45.00M | 21.00M | 9.00M | 12.00M | 18.00M | 42.00M | 71.00M | 40.00M | 9.00M | 18.00M | 23.81M | 10.71M | 20.46M | 0.00 | 17.03M | 11.16M | 16.27M | 20.66M | 17.13M | 17.46M | 16.88M | 35.50M | 40.65M | 65.30M | 84.49M | 55.04M | 47.03M | 44.97M | 24.10M | 26.22M |
| Depreciation & Amortization | 527.00M | 548.00M | 563.00M | 545.00M | 496.00M | 427.00M | 435.00M | 415.00M | 445.00M | 351.00M | 297.00M | 324.00M | 306.00M | 288.00M | 312.00M | 287.00M | 237.00M | 169.00M | 180.00M | 137.33M | 143.21M | 152.05M | 87.81M | 79.16M | 87.84M | 82.00M | 67.45M | 72.78M | 61.19M | 57.22M | 53.25M | 49.29M | 52.95M | 51.12M | 36.75M | 33.34M | 35.60M | 24.69M | 20.17M |
| EBITDA | 979.00M | 1.00B | 1.22B | 839.00M | 1.43B | 1.29B | 1.39B | 1.53B | 1.07B | 1.28B | 1.19B | 1.18B | 1.16B | 1.25B | 1.01B | 936.00M | 721.00M | 703.00M | 591.00M | 250.00M | 265.00M | 362.43M | 313.67M | 409.69M | 361.29M | 305.02M | 340.04M | 395.93M | 351.84M | 65.51M | 332.67M | 324.42M | 249.80M | 390.42M | 314.83M | 295.16M | 279.73M | 179.18M | 148.10M |
| EBITDA Ratio | 17.64% | 21.36% | 22.60% | 20.33% | 27.77% | 28.61% | 27.49% | 28.42% | 25.68% | 27.79% | 27.24% | 28.57% | 27.31% | 30.57% | 27.55% | 24.63% | 25.59% | 26.92% | 27.82% | 26.58% | 26.29% | 24.52% | 20.01% | 21.99% | 21.06% | 19.96% | 20.41% | 21.68% | 22.29% | 22.72% | 22.60% | 23.50% | 24.48% | 27.74% | 27.63% | 27.40% | 27.32% | 25.24% | 24.30% |
| Operating Income | 425.00M | 665.00M | 712.00M | 433.00M | 981.00M | 976.00M | 875.00M | 912.00M | 745.00M | 932.00M | 888.00M | 846.00M | 862.00M | 920.00M | 723.00M | 630.00M | 493.00M | 537.00M | 422.00M | 317.06M | 321.07M | 242.73M | 225.86M | 214.78M | 178.43M | 209.98M | 269.29M | 311.50M | 253.11M | 215.12M | 238.60M | 214.92M | 252.61M | 339.30M | 278.08M | 261.82M | 244.13M | 154.49M | 127.93M |
| Operating Income Ratio | 7.66% | 12.75% | 13.66% | 9.50% | 19.09% | 19.90% | 18.36% | 19.53% | 16.08% | 20.19% | 20.41% | 20.45% | 20.19% | 23.22% | 19.17% | 16.57% | 14.63% | 19.32% | 16.54% | 13.24% | 15.25% | 13.58% | 14.34% | 12.67% | 9.85% | 12.01% | 15.54% | 17.01% | 15.96% | 14.26% | 17.00% | 16.52% | 17.05% | 24.11% | 24.41% | 24.30% | 23.85% | 21.77% | 20.99% |
| Total Other Income/Expenses | -135.00M | -215.00M | -7.00M | -49.00M | -72.00M | -82.00M | -55.00M | 150.00M | -69.00M | -35.00M | -8.00M | 242.00M | -14.00M | -25.00M | -53.00M | -66.00M | -24.00M | 35.00M | -54.00M | 2.00M | -9.00M | 43.83M | -15.58M | -10.47M | 116.15M | 13.28M | -17.36M | -5.48M | 20.09M | -223.72M | 5.33M | 19.57M | -121.07M | -84.49M | -55.04M | -47.03M | -44.97M | -24.10M | -26.22M |
| Income Before Tax | 290.00M | 235.00M | 586.00M | 246.00M | 743.00M | 781.00M | 879.00M | 1.06B | 559.00M | 714.00M | 802.00M | 1.10B | 848.00M | 895.00M | 670.00M | 564.00M | 469.00M | 550.00M | 428.00M | 345.83M | 410.89M | 290.73M | 210.28M | 396.10M | 294.58M | 223.26M | 251.93M | 306.02M | 273.19M | -8.60M | 243.92M | 234.48M | 131.54M | 254.81M | 223.04M | 214.79M | 199.16M | 130.39M | 101.71M |
| Income Before Tax Ratio | 5.23% | 4.51% | 11.24% | 5.39% | 14.46% | 15.93% | 18.45% | 22.75% | 12.06% | 15.46% | 18.43% | 26.59% | 19.86% | 22.59% | 17.76% | 14.84% | 13.92% | 19.79% | 16.77% | 14.44% | 19.52% | 16.26% | 13.35% | 23.37% | 16.26% | 12.77% | 14.54% | 16.71% | 17.23% | -0.57% | 17.38% | 18.02% | 8.88% | 18.10% | 19.57% | 19.94% | 19.45% | 18.37% | 16.69% |
| Income Tax Expense | 27.00M | 12.00M | 62.00M | 202.00M | 143.00M | 118.00M | 112.00M | 278.00M | 149.00M | 213.00M | 246.00M | 371.00M | 266.00M | 280.00M | 198.00M | 187.00M | 153.00M | 156.00M | 126.00M | 85.55M | 146.43M | 105.98M | 93.20M | 86.18M | 125.05M | 67.72M | 63.98M | 99.33M | 98.89M | 75.67M | 83.13M | 67.95M | 43.79M | 65.01M | 59.53M | 64.33M | 58.64M | 41.10M | 33.14M |
| Net Income | 263.00M | 223.00M | 524.00M | 448.00M | 600.00M | 663.00M | 767.00M | 784.00M | 410.00M | 501.00M | 556.00M | 729.00M | 582.00M | 615.00M | 472.00M | 377.00M | 316.00M | 745.00M | 333.00M | 290.01M | 264.46M | 184.75M | 188.72M | 309.92M | 169.54M | 155.53M | 187.96M | 206.70M | 174.30M | -84.27M | 160.79M | 155.92M | 74.66M | 143.13M | 147.63M | 145.24M | 140.52M | 89.29M | 68.43M |
| Net Income Ratio | 4.74% | 4.28% | 10.05% | 9.82% | 11.68% | 13.52% | 16.10% | 16.79% | 8.85% | 10.85% | 12.78% | 17.62% | 13.63% | 15.52% | 12.51% | 9.92% | 9.38% | 26.81% | 13.05% | 12.11% | 12.56% | 10.33% | 11.98% | 18.29% | 9.36% | 8.90% | 10.85% | 11.29% | 10.99% | -5.59% | 11.46% | 11.99% | 5.04% | 10.17% | 12.96% | 13.48% | 13.73% | 12.58% | 11.23% |
| EPS | 0.60 | 0.51 | 1.20 | 1.02 | 1.37 | 0.76 | 0.88 | 0.88 | 0.46 | 0.56 | 0.61 | 1.63 | 1.31 | 1.39 | 1.07 | 0.85 | 0.68 | 1.58 | 0.71 | 0.57 | 0.57 | 0.20 | 0.20 | 0.30 | 0.18 | 0.17 | 0.21 | 0.23 | 0.19 | -0.09 | 0.19 | 0.19 | 0.09 | 0.18 | 0.18 | 0.18 | 0.18 | 0.16 | 0.20 |
| EPS Diluted | 0.60 | 0.51 | 1.19 | 1.02 | 1.37 | 0.76 | 0.88 | 0.88 | 0.46 | 0.56 | 0.61 | 1.62 | 1.30 | 1.38 | 1.07 | 0.85 | 0.68 | 1.58 | 0.71 | 0.56 | 0.56 | 0.19 | 0.20 | 0.30 | 0.18 | 0.17 | 0.21 | 0.23 | 0.19 | -0.09 | 0.19 | 0.19 | 0.09 | 0.18 | 0.18 | 0.18 | 0.18 | 0.16 | 0.20 |
| Weighted Avg Shares Out | 435.50M | 436.00M | 438.50M | 437.50M | 437.00M | 875.83M | 874.57M | 892.94M | 899.00M | 899.46M | 905.54M | 448.50M | 445.50M | 444.00M | 441.95M | 443.00M | 461.50M | 470.50M | 465.00M | 467.50M | 465.00M | 925.68M | 921.00M | 1.03B | 801.94M | 908.18M | 908.20M | 904.11M | 896.75M | 889.38M | 842.75M | 823.11M | 817.38M | 811.65M | 802.25M | 791.20M | 778.11M | 551.88M | 333.83M |
| Weighted Avg Shares Out (Dil) | 436.88M | 436.50M | 439.00M | 438.50M | 438.50M | 876.00M | 875.00M | 893.00M | 899.00M | 899.00M | 906.00M | 450.50M | 447.50M | 444.50M | 442.78M | 445.00M | 464.00M | 472.00M | 471.50M | 470.50M | 468.00M | 954.24M | 929.55M | 1.03B | 803.65M | 910.35M | 910.66M | 904.11M | 896.75M | 889.38M | 842.75M | 823.11M | 817.38M | 811.65M | 802.25M | 791.20M | 778.11M | 551.88M | 333.83M |
Smith & Nephew has the potential to pop next year, says leading US investment bank
JP Morgan has doubled down on its "overweight" recommendation for Smith & Nephew PLC (LSE:SN) with its analysts deeming the medical device company undervalued, trading near trough levels, with potential for significant re-rating. Despite challenges in the broader European medtech sector,...
Big investors call for break-up of Smith & Nephew, FT reports
Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's...
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital...
Smith+Nephew slashes revenue outlook as China headwinds emerge
British medical equipment manufacturer Smith & Nephew PLC (LSE:SN) slashed its full-year revenue outlook to account for a downturn in demand and pricing pressures in the Chinese market. The FTSE 100-listed group now expects full-year revenue growth of 4.5%, compared...
Smith & Nephew slashes annual revenue forecast on weak China
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology...
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only...
Source: https://incomestatements.info
Category: Stock Reports